Rznomics
Rznomics is a biotech company founded in August 2017, specializing in the development of gene therapies based on RNA platform technology. The company aims to create innovative treatments for cancer, intractable diseases, genetic disorders, and neurodegenerative conditions through its core RNA technology platform, including trans-splicing ribozymes and gene editing tools. Recognized for its technological excellence, Rznomics has been involved in multiple national projects and holds numerous patents in the field of RNA-based therapeutics.
Industries
Nr. of Employees
small (1-50)
Products
Gene therapy candidate for hepatocellular carcinoma (TERT-targeting, adenoviral)
A viral-vector delivered gene therapy candidate targeting telomerase reverse transcriptase (TERT) for hepatocellular carcinoma, developed for intratumoral administration and progressed to Phase I.
Hepatocellular carcinoma combination candidate (TERT-targeting + immune therapy)
A combination development program pairing a TERT-targeting viral gene therapy administered intratumorally with systemic immune-modulating therapy in early clinical studies.
Glioblastoma gene therapy candidates (TERT-targeting)
Viral-vector delivered TERT-targeting gene therapy programs for glioblastoma in preclinical and Phase I stages, designed for intra-tumoral administration.
Alzheimer’s disease candidate (APOE4-targeting, AAV)
A discovery-stage gene therapy program targeting APOE4 transcripts for Alzheimer’s disease, employing adeno-associated virus (AAV) delivery intended for intracisternal administration.
Retinitis pigmentosa candidate (mutant rhodopsin-targeting, AAV)
A preclinical gene therapy candidate designed to correct mutant rhodopsin transcripts for retinitis pigmentosa, delivered via adeno-associated virus with sub-retinal administration.
Gene therapy candidate for hepatocellular carcinoma (TERT-targeting, adenoviral)
A viral-vector delivered gene therapy candidate targeting telomerase reverse transcriptase (TERT) for hepatocellular carcinoma, developed for intratumoral administration and progressed to Phase I.
Hepatocellular carcinoma combination candidate (TERT-targeting + immune therapy)
A combination development program pairing a TERT-targeting viral gene therapy administered intratumorally with systemic immune-modulating therapy in early clinical studies.
Glioblastoma gene therapy candidates (TERT-targeting)
Viral-vector delivered TERT-targeting gene therapy programs for glioblastoma in preclinical and Phase I stages, designed for intra-tumoral administration.
Alzheimer’s disease candidate (APOE4-targeting, AAV)
A discovery-stage gene therapy program targeting APOE4 transcripts for Alzheimer’s disease, employing adeno-associated virus (AAV) delivery intended for intracisternal administration.
Retinitis pigmentosa candidate (mutant rhodopsin-targeting, AAV)
A preclinical gene therapy candidate designed to correct mutant rhodopsin transcripts for retinitis pigmentosa, delivered via adeno-associated virus with sub-retinal administration.
Services
Collaborative preclinical and clinical development partnerships
Partnership-based research and co-development arrangements to advance viral-delivered RNA therapeutics from preclinical stages into early clinical testing.
Collaborative preclinical and clinical development partnerships
Partnership-based research and co-development arrangements to advance viral-delivered RNA therapeutics from preclinical stages into early clinical testing.
Expertise Areas
- RNA therapeutics and transcript-level editing
- Gene therapy candidate development
- Viral vector in vivo delivery (adenovirus, AAV)
- Preclinical efficacy and safety evaluation
Key Technologies
- Trans-splicing ribozyme RNA replacement
- Self-circularizing RNA constructs
- Adenoviral vectors
- Adeno-associated virus (AAV) vectors